Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar in Type 2 Diabetes Mellitus (GALLEX 9)
NCT00229710Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Feb 2005
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tesaglitazar in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Primary endpoints: Incidence of adverse events at 140 weeks, Clinical laboratory variables at 140 weeks and 6 more. Started Feb 2005; status: terminated.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00229710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00229710.